Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accounts Payables (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Accounts Payables for 7 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 164.3% to $10.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 164.3% increase, with the full-year FY2025 number at $10.2 million, up 164.3% from a year prior.
  • Accounts Payables was $10.2 million for Q4 2025 at Beam Therapeutics, up from $9.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.1 million in Q1 2023 to a low of $1.6 million in Q4 2023.
  • A 5-year average of $6.9 million and a median of $7.2 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 82.09% in 2023, then skyrocketed 175.95% in 2025.
  • Beam Therapeutics' Accounts Payables stood at $7.5 million in 2021, then increased by 20.81% to $9.0 million in 2022, then tumbled by 82.09% to $1.6 million in 2023, then soared by 139.39% to $3.9 million in 2024, then skyrocketed by 164.3% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Accounts Payables are $10.2 million (Q4 2025), $9.5 million (Q3 2025), and $10.6 million (Q2 2025).